Inventor · disambiguated record
Rachel Rebecca Barrett
Also filed as: BARRETT RACHEL REBECCA
13 granted patents·10 pending applications·136 citations·filing 2011–2024
91Inventor score
Top patents by PatentIndex Score
23 records- 0196US8591900B2Anti-CD40 antibodiesBARRETT RACHEL REBECCA·Filed 2011·Granted Nov 26, 2013·53 cites·42 claims
- 0295US9090696B2Polynucleotides encoding anti-CD40 antibodiesBARRETT RACHEL REBECCA·Filed 2013·Granted Jul 28, 2015·33 cites·4 claims
- 0392US8778346B2Anti-IL-23 antibodiesBARRETT RACHEL REBECCA·Filed 2011·Granted Jul 15, 2014·26 cites·46 claims
- 0488US9441036B2Anti-IL-23 antibodiesBARRETT RACHEL REBECCA·Filed 2014·Granted Sep 13, 2016·10 cites·14 claims
- 0586US11242394B2Anti-CD40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2018·Granted Feb 8, 2022·3 cites·43 claims
- 0686US2025101093A1Anti-il-23 antibodiesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 0785US10202448B2Anti-IL-23 antibodiesBOEHRINGER INGELHEIM INT·Filed 2016·Granted Feb 12, 2019·4 cites·9 claims
- 0881US10793629B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2018·Granted Oct 6, 2020·1 cites·35 claims
- 0981US10280231B2Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereofBOEHRINGER INGELHEIM INT·Filed 2016·Granted May 7, 2019·3 cites·18 claims
- 1079US11267880B2Anti-Sema3A antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2020·Granted Mar 8, 2022·1 cites·26 claims
- 1179US2023382988A1Compound targeting il-23a and tnf-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 1279US2022153857A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 1377US10059763B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2015·Granted Aug 28, 2018·2 cites·23 claims
- 1475US2024336674A1Anti-sema3a antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2024·Application pending·0 cites
- 1572US2021198355A1Anti-il-23 antibodiesBOEHRINGER INGELHEIM INT·Filed 2020·Application pending·0 cites
- 1671US11680096B2Compound targeting IL-23A and TNF-alpha and uses thereofBOEHRINGER INGELHEIM INT·Filed 2020·Granted Jun 20, 2023·0 cites·25 claims
- 1767US2022144929A1Anti-sema3a antibodies and their uses for treating eye or ocular diseasesBOEHRINGER INGELHEIM INT·Filed 2022·Application pending·0 cites
- 1866US11884744B2Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereofBOEHRINGER INGELHEIM INT·Filed 2020·Granted Jan 30, 2024·0 cites·20 claims
- 1964US2019144534A1Anti-il-23 antibodiesBOEHRINGER INGELHEIM INT·Filed 2019·Application pending·0 cites
- 2063US10844138B2Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereofBOEHRINGER INGELHEIM INT·Filed 2019·Granted Nov 24, 2020·0 cites·15 claims
- 2161US2017058039A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
- 2260US2016222124A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2016·Application pending·0 cites
- 2357US2015315282A1Anti-cd40 antibodiesBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →